# Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

> **NCT06498635** · PHASE3 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 306 (estimated)

## Conditions studied

- Lung Non-Small Cell Carcinoma
- Stage II Lung Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Durvalumab
- **OTHER:** Patient Observation
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT06498635
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2039-07-15
- **Final completion:** 2039-07-15
- **Target enrollment:** 306 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06498635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06498635, "Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT06498635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*